Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis
- 30 September 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 74 (1), 29-35
- https://doi.org/10.1007/s00228-017-2338-8
Abstract
Early and intensive atorvastatin treatment can decrease nonsustained ventricular tachycardia (nsVT) in patients with ST-segment elevation myocardial infarction (STEMI). The objective of this study was to compare the effects of hydrophilic rosuvastatin and lipophilic atorvastatin on nsVT in STEMI patients treated with primary percutaneous coronary intervention (PCI). The data from a cohort of patients undergoing primary PCI at Jinhua Municipal Central Hospital from January 1, 2013 through June 30, 2016 were analyzed. The patients were divided into the rosuvastatin group and the atorvastatin group based on which kind of statins that they had received. The endpoint of the study was the occurrence of nsVT on either electrocardiogram monitoring or Holter monitoring. A total of 301 patients were enrolled in the study (rosuvastatin group: n = 103; atorvastatin group: n = 198). The baseline and procedural characteristics were similar between the two groups, except that total ischemic time in the rosuvastatin group was markedly longer than that in the atorvastatin group (8 (5-16) h vs. 6 (4-12) h; P = 0.001). The administration of rosuvastatin was significantly associated with lower occurrence of nsVT than that of atorvastatin (9.71 vs. 19.70%; P = 0.026). Multivariable logistic regression analysis suggested that the independent predictors of nsVT included rosuvastatin (odds ratio (OR) 0.397, 95% confidence interval (CI) 0.176-0.894), current smoking (OR 2.307, 95% CI 1.011-5.262), and left ventricular ejection fraction (LVEF) (OR 1.060, 95% CI 1.023-1.098). The effects of rosuvastatin on nsVT might be better than that of atorvastatin in STEMI patients undergoing primary PCI.Keywords
This publication has 40 references indexed in Scilit:
- Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial InfarctionThe Korean Journal of Internal Medicine, 2011
- Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)American Heart Journal, 2007
- Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplastyEuropean Heart Journal, 2007
- Usefulness of Hydrophilic vs Lipophilic Statins After Acute Myocardial Infarction Subanalysis of MUSASHI-AMICirculation Journal, 2007
- Atorvastatin Therapy Increases Heart Rate Variability, Decreases QT Variability, and Shortens QTc Interval Duration in Patients With Advanced Chronic Heart FailureJournal of Cardiac Failure, 2005
- Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment eraEuropean Heart Journal, 2005
- Disparity between angiographic regression and clinical event rates with hydrophobic statinsThe Lancet, 2002
- Effect of fluvastatin on qt dispersion: a new pleiotropic effect?The American Journal of Cardiology, 2000
- Prognostic implications of ventricular ectopy one week, one month, and sixteen months after an acute myocardial infarctionClinical Cardiology, 1998
- Clinical significance of ventricular tachycardia (3 beats or longer) detected during ambulatory monitoring after myocardial infarction.Circulation, 1978